Second-Line Immunotherapy Treatment Fails to Improve Mesothelioma Survival – Surviving Mesothelioma
Surviving Mesothelioma |
Second-Line Immunotherapy Treatment Fails to Improve Mesothelioma Survival
Surviving Mesothelioma A large international clinical trial of the immunotherapy drug tremelimumab as a second- or third-line treatment option for malignant mesothelioma has produced some disappointing news. Drug maker AstraZeneca has just released an update on the ongoing … |
